Xenon Pharmaceuticals (XENE) Misses Q3 EPS by 6c

Xenon Pharmaceuticals (NASDAQ: XENE) reported Q3 EPS of ($0.57), $0.06 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $130 thousand versus the consensus estimate of $4.15 million.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• AMC Entertainment prices $200M stock offering to redeem senior notes
• Ares Management, L.P. (ARES) PT Raised to $153 at TD Cowen